Dr. Brian C. Orr, MD
Gynecologic Oncology (Gynecologic Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Tennessee, Hsc, College of Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 230
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: University of Tennessee, Hsc, College of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecologic Oncology Physician primary
SC license 84923 · PA license MD451425 -
Obstetrics & Gynecology Physician
SC license 84923 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Musc Medical Center Charleston, SC
- Musc Health Columbia Medical Center Downtown Columbia, SC
- Musc Health Florence Medical Center Florence, SC
- Beaufort County Memorial Hospital Beaufort, SC
Medical groups
- University Medical Associates of the Medical University of South Carol (1,668 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 230
- Services billed
- 860
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 387 | 163 |
| New patient office or other outpatient visit, 60-74 minutes | 72 | 72 |
| Established patient office or other outpatient visit, 20-29 minutes | 70 | 63 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 59 | 28 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 27 | 17 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 26 | 26 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Charleston, SC | 59 |
| Eliquis (apixaban) Other prescribers in Charleston, SC | 34 |
| Tramadol Hcl Other prescribers in Charleston, SC | 32 |
| Ondansetron Hcl Other prescribers in Charleston, SC | 30 |
| Oxycodone Hcl Other prescribers in Charleston, SC | 21 |
| Estradiol Other prescribers in Charleston, SC | 20 |
| Amlodipine Besylate Other prescribers in Charleston, SC | 15 |
| Prochlorperazine Maleate Other prescribers in Charleston, SC | 13 |
| Lynparza (olaparib) | 13 |
| Dexamethasone Other prescribers in Charleston, SC | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $25.70 in total to this clinician.
| Merck Sharp & Dohme LLC | $25.70 |
|---|
| Education | $25.70 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Mar 25, 2025 | Education KEYTRUDA · ONCOLOGY · in-kind | $25.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $20,367 in research payments for these studies, mostly to the institutions running them.
- A phase i open-label, multicenter study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of SAIL66 in patients with CLDN6-POSITIVE locally advanced or metastatic solid tumors
Chugai Pharmaceutical Co., Ltd. - A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
Daiichi Sankyo Inc. · Active, not recruiting · NCT04707248
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.